Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 7/20 | 0.52 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.52 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.47 |
| ▸ | CCNK | O75909 | 6/20 | 0.46 |
| ▸ | CDK12 | Q9NYV4 | 6/20 | 0.46 |
| ▸ | CDK7 | P50613 | 5/20 | 0.44 |
| ▸ | CCNH | P51946 | 5/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CDK9 | P50750 | 2/20 | 0.44 |
| ▸ | MNAT1 | P51948 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21629046 | 0.86 | CCNK (0.44) | MEN1KMT2ACCNKCDK12CDK7 | |
| SCHEMBL30554768 | 0.86 | CCNK (0.44) | MEN1KMT2ACCNKCDK12CDK7 | |
| SCHEMBL21188462 | 0.86 | CLK1 (0.69) | CLK1CDK5CDK5R1GSK3BDYRK1A | |
| SCHEMBL29488124 | 0.84 | CLK1 (0.55) | CLK1CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL29488129 | 0.84 | MAP3K14 (0.65) | CLK1CDK5CDK5R1MEN1KMT2A | |
| SCHEMBL21026876 | 0.83 | CDK5 (0.69) | CLK1CDK5CDK5R1GSK3BDYRK1A | |
| SCHEMBL26043640 | 0.82 | CCNK (0.60) | CLK1CDK5CDK5R1GSK3BDYRK1A | |
| SCHEMBL26043638 | 0.81 | CCNK (0.51) | CLK1CDK5CDK5R1CCNKCDK12 | |
| SCHEMBL21184546 | 0.81 | CCNK (0.64) | CLK1CDK5CDK5R1CCNKCDK12 | |
| SCHEMBL29614769 | 0.79 | CLK1 (0.59) | CLK1CDK5CDK5R1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | HANMI PHARM. CO., LTD. (KR) | 2025-07-08 | — | — | US | claimed |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | HANMI PHARM. CO., LTD. (KR) | 2022-11-10 | — | — | US | claimed |
| US-11292786-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | HANMI PHARM. CO., LTD. (KR) | 2022-04-05 | — | — | US | claimed |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | HANMI PHARM. CO., LTD. (KR) | 2025-07-08 | — | — | US | disclosed |
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | HANMI PHARM. CO., LTD. (KR) | 2022-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354842-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE MYELOID LEUKEMIA, CONTAINING FLT3 INHIBITOR AND CHEMOTHERAPEUTIC AGENTS | FLT3, MCL1, CSF3R | CLK1 641/4885CDK5 845/4885CDK5R1 1910/4885 |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | FLT3, MCL1, CSF3R | CLK1 641/4885CDK5 845/4885CDK5R1 1910/4885 |
| US-11292786-B2 | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same | DPYD, TYMS, TYMP | CLK1 3577/4885CDK5 438/4885CDK5R1 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.